About Azora Therapeutics
Azora Therapeutics is a Healthcare company based in Los Angeles (United States) founded in 2019 by Matt Davidson, and was acquired by Adial Pharmaceuticals in June 2026. Small molecule therapies for autoinflammatory diseases are developed. Azora Therapeutics has raised $581.45 thousand across 1 funding round from investors including Adial Pharmaceuticals. Its chief executive, as recorded, is Matt Davidson. Azora Therapeutics offers products and services including AT177 and AT193. Its focus areas include Life Sciences, Immunology, Drugs and Inflammatory Diseases. Its legal entity is Azora Therapeutics Inc. Its competitors include Aclaris Therapeutics, Escient Pharmaceuticals and Nimbus Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Azora Therapeutics was founded in 2019 in Los Angeles, United States, within the biotechnology sector. Small molecule formulations are developed to activate the AhR pathway in the skin and colon, aiming to modulate immune responses for inflammatory conditions. Operations center on advancing treatments for diseases such as Hidradenitis Suppurativa, nail psoriasis, and ulcerative colitis, with AT-193 as the primary candidate under evaluation.
- Headquarters Los Angeles, United States
- Founders Matt Davidson
- Stage Acquired
- SectorsHealthcare
- Website azoratherapeutics.com
- Social LinkedIn Facebook
- Acquired by Adial Pharmaceuticals (Jun 2026)
- Legal Name Azora Therapeutics Inc
- Total Equity Funding$581.45K (USD)
in 1 rounds
- Latest Funding Round$581.45K (USD), Seed
Aug 2023
- Investors
- Acquired byAdial Pharmaceuticals
(Jun 2026)
Products & Services of Azora Therapeutics
Azora Therapeutics offers a comprehensive portfolio of products and services, including AT177 and AT193.
Investigational small molecule for autoimmune diseases treatment
Investigational therapy for serious inflammatory conditions
Funding Insights of Azora Therapeutics
Azora Therapeutics has successfully raised a total of $581.45K through 1 strategic funding round. The most recent funding activity was a Seed round of $581.45 thousand completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $581,449
- Total Rounds 1
- Last Round Seed — $581,449
- First Round $581,449
(Aug 2023)
All 1 funding rounds of Azora Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $581,449 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Azora Therapeutics
Azora Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Adial Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapeutics for addiction treatment are developed by Adial Pharmaceuticals. | 2010 | adial.com | Charlottesville, United States |
Investor details for Azora Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Azora Therapeutics
1 people are tracked at Azora Therapeutics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Matt Davidson | Co-Founder & CEO | Leadership |
Complete people profiles for Azora Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Azora Therapeutics
3 dated milestones of Azora Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Azora Therapeutics is founded.
- Funding First funding round of $581K.
- Exit Acquired by Adial Pharmaceuticals.
Competitors of Azora Therapeutics
Azora Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Aclaris Therapeutics, Escient Pharmaceuticals and Nimbus Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Azora Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Azora Therapeutics
The website of Azora Therapeutics (azoratherapeutics.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 95.9% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Azora Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Azora Therapeutics
Azora Therapeutics was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Azora Therapeutics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Matt Davidson is the CEO of Azora Therapeutics, as recorded in our data. They have also founded this company.
Azora Therapeutics is a funded company, having raised a total of $581.45K across 1 funding round to date. The company's 1st funding round was a Seed of $581.45K, raised on Aug 2023.
Azora Therapeutics was founded in 2019 in Los Angeles, United States, within the biotechnology sector. Small molecule formulations are developed to activate the AhR pathway in the skin and colon, aiming to modulate immune responses for inflammatory conditions. Operations center on advancing treatments for diseases such as Hidradenitis Suppurativa, nail psoriasis, and ulcerative colitis, with AT-193 as the primary candidate under evaluation.
Azora Therapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Aclaris Therapeutics.
Azora Therapeutics offers AT177 and AT193.
Azora Therapeutics has 1 investor. Key investors include Adial Pharmaceuticals.
Azora Therapeutics operates through Azora Therapeutics Inc.
Yes. Azora Therapeutics was acquired by Adial Pharmaceuticals in June 2026.